(Reuters) – GlaxoSmithKline Plc said on Saturday its asthma drug, Nucala, which is already approved in the United States and Europe, showed a similar safety profile in a long-term study compared with previous studies. GSK said Nucala, which is administered once every four weeks by injection, maintained its risk/benefit profile over an extended 52-week period. The drug is an antibody that reduces the levels of eosinophils – a type of white blood cells – that contributes to asthma.
Here is the original:
GSK asthma drug Nucala’s long-term study supports safety profile